临床癌症护理中的PAM-13:系统性审查
Kenzy Jean Pierre1, Elise Verot2, Wafa Bouleftour1
1Department of Medical Oncology, Saint-Etienne University Hospital-Etienne, Saint-Etienne, France.
Archives of medical research
|December 20, 2024
概括
通过患者激活测量-13 (PAM-13) 测量患者激活,受患者特征和程序类型的影响. 与数字干预相比,非数字干预在癌症护理中表现出更高的有效性.
科学领域:
- 在瘤学瘤学.
- 医疗保健服务研究 医疗服务研究
- 患者参与 患者参与
背景情况:
- 患者激活措施-13 (PAM-13) 是评估患者自我健康管理能力的工具.
- 了解影响患者激活的因素对于改善医疗保健结果至关重要.
研究的目的:
- 系统地审查PAM-13分数与患者特征之间的关系.
- 评估不同医疗保健计划在癌症护理中患者激活方面的有效性.
主要方法:
- 使用PubMed进行了系统的文献搜索.
- 在研究选择和查方面遵循了PRISMA指南.
- 在最终分析中包含了21篇文章.
主要成果:
- 一半的单一类型癌症研究的焦点是乳腺癌.
- 非数字程序 (75%有效率) 在改善癌症护理中的PAM-13分数方面比数字程序 (14.29%有效率) 更有效.
- 患者的特征,如教育水平,对复发的恐惧和与医疗保健提供者的时间,影响了激活水平.
结论:
- 本综述强调了PAM-13,患者因素和瘤学项目有效性之间的联系.
- 需要进一步的研究来验证使用PAM-13的干预措施.
- 建议加强数字健康倡议,以优化癌症护理.
更多相关视频
07:43Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
10.5K
07:40Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
16.5K
相关概念视频
Cancer Therapies
8.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.6K
Targeted Cancer Therapies
7.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.1K
Treatment Resistant Cancers
2.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.7K
Combination Therapies and Personalized Medicine
5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Clinical Trials: Overview
4.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K
Cancer Survival Analysis
870
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
870
